[18F] JNJ 64413739
Alternative Names: 18F-JNJ-64413739; 18F-JNJ64413739-PET tracer - Janssen PharmaceuticaLatest Information Update: 26 Apr 2023
At a glance
- Originator Janssen Pharmaceutica
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 03 Mar 2023 Kepler University Hospital plans a Proof-of-principle imaging study for Glioblastoma in July 2023 (NCT05753995)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Major depressive disorder(Diagnosis, In volunteers) in Belgium (IV, Injection)
- 01 Sep 2020 Enigma Biomedical Group plans a preclinical and clinical studies in Neurodegenerative diseases